Addiction Research

According to the World Health Organization (WHO), addiction is 'a chronic disease of the central nervous system that is characterized by a loss of control over impulsive behavior that leads to compulsive drug seeking and taking, and to relapses even after months of abstinence'. Addiction is a complex neuroadaptive process, where drugs of abuse alter cellular and molecular aspects of neural function. The brain circuits mediating the various behavioral effects of these drugs are rendered more, or less, responsive to those effects.

Addiction Research Products Targets

Products for Addiction Research - Page 12

Cat.No. Product Name Information/Activity
BCN2170 Varenicline tartrate Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.
BCC7341 Dihydro-β-erythroidine hydrobromide Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active and competitive antagonist of neuronal nicotinic acetyicholine receptors (nAChRs). Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities.
BCC7301 DMAB-anabaseine dihydrochloride 154149-38-9
BCC7651 Desformylflustrabromine hydrochloride Desformylflustrabromine hydrochloride is a selective agonist of α4β2 neuronal nicotinic acetylcholine receptor (nAChR) with a pEC50 of 6.48.
BCC7869 LY 2087101 913186-74-0
BCC7468 Sazetidine A dihydrochloride 1197329-42-2
BCC7920 A 582941 848591-90-2
BCC6200 A 844606 861119-08-6
BCC7827 AR-R 17779 hydrochloride 178419-42-6
BCC7948 GTS 21 dihydrochloride GTS-21 dihydrochloride is a selective α7 nicotinic acetylcholine receptor agonist, has recently been established as a promising treatment for inflammation.